Paclitaxel repackaged in an albumin-stabilized nanoparticle: Handy or just a dandy?

被引：25

作者：

Sparreboom, A ^{[1
]}

Baker, SD

Verweij, J

机构：

[1] NCI, Bethesda, MD 20892 USA

[2] Erasmus Univ, Ctr Med, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands

[3] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 31期

关键词：

D O I：

10.1200/JCO.2005.03.7135

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：7765 / 7767

页数：3

共 24 条

[1] Pharmaceutical excipient development: The need for preclinical guidance [J].

Baldrick, P .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2000, 32 (02) :210-218

[2] Potential for improvement of docetaxel-based chemotherapy: a pharmacological review [J].

Engels, FK ;

Sparreboom, A ;

Mathot, RAA ;

Verweij, J .

BRITISH JOURNAL OF CANCER, 2005, 93 (02) :173-177

[3] Docetaxel administration schedule: From fever to tears? A review of randomised studies [J].

Engels, FK ;

Verweij, J .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (08) :1117-1126

[4] NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS [J].

GIANNI, L ;

KEARNS, CM ;

GIANI, A ;

CAPRI, G ;

VIGANO, L ;

LOCATELLI, A ;

BONADONNA, G ;

EGORIN, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :180-190

[5] Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [J].

Gradishar, WJ ;

Tjulandin, S ;

Davidson, N ;

Shaw, H ;

Desai, N ;

Bhar, P ;

Hawkins, M ;

O'Shaughnessy, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7794-7803

[6] Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks [J].

Green, MC ;

Buzdar, AU ;

Smith, T ;

Ibrahim, NK ;

Valero, V ;

Rosales, MF ;

Cristofanilli, M ;

Booser, DJ ;

Pusztai, L ;

Rivera, E ;

Theriault, RL ;

Carter, C ;

Frye, D ;

Hunt, KK ;

Symmans, WF ;

Strom, EA ;

Sahin, AA ;

Sikov, W ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5983-5992

[7]

HARRIS JW, 1994, CANCER RES, V54, P4026

[8] Mechanism-based pharmacokinetic model for paclitaxel [J].

Henningsson, A ;

Karlsson, MO ;

Viganò, L ;

Gianni, L ;

Verweij, J ;

Sparreboom, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) :4065-4073

[9] Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel [J].

Hopper-Borge, E ;

Chen, ZS ;

Shchaveleva, I ;

Belinsky, MG ;

Kruh, GD .

CANCER RESEARCH, 2004, 64 (14) :4927-4930

[10] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid [J].

Huisman, MT ;

Chhatta, AA ;

van Tellingen, O ;

Beijnen, JH ;

Schinkel, AH .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (05) :824-829

← 1 2 3 →